

Vesicular dysfunction and the pathogenesis of Parkinson's disease: clues from genetic studies

Article

Published Version

Creative Commons: Attribution 4.0 (CC-BY)

Open access

Ebanks, K., Lewis, P. A. and Bandopadhyay, R. (2020)
Vesicular dysfunction and the pathogenesis of Parkinson's
disease: clues from genetic studies. *Frontiers in Neuroscience*,
13. 1381. ISSN 1662-453X doi: 10.3389/fnins.2019.01381
Available at <https://centaur.reading.ac.uk/87743/>

It is advisable to refer to the publisher's version if you intend to cite from the work. See [Guidance on citing](#).

To link to this article DOI: <http://dx.doi.org/10.3389/fnins.2019.01381>

Publisher: Frontiers

All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the [End User Agreement](#).

www.reading.ac.uk/centaur

CentAUR

Central Archive at the University of Reading

Reading's research outputs online



Vesicular Dysfunction and the Pathogenesis of Parkinson's Disease: Clues From Genetic Studies

Kirsten Ebanks^{1,2}, Patrick A. Lewis^{3,4} and Rina Bandopadhyay^{1,2*}

¹ Reta Lila Weston Institute, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom,

² Department of Clinical and Motor Neuroscience, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom, ³ School of Pharmacy, University of Reading, Reading, United Kingdom, ⁴ Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, United Kingdom

OPEN ACCESS

Edited by:

Vincenzo La Bella,
University of Palermo, Italy

Reviewed by:

Sabine Hilfiker,
Spanish National Research Council
(CSIC), Spain
Petr A. Slominsky,
Institute of Molecular Genetics (RAS),
Russia

*Correspondence:

Rina Bandopadhyay
rina.bandopadhyay@ucl.ac.uk

Specialty section:

This article was submitted to
Neurodegeneration,
a section of the journal
Frontiers in Neuroscience

Received: 11 October 2019

Accepted: 05 December 2019

Published: 08 January 2020

Citation:

Ebanks K, Lewis PA and
Bandopadhyay R (2020) Vesicular
Dysfunction and the Pathogenesis
of Parkinson's Disease: Clues From
Genetic Studies.
Front. Neurosci. 13:1381.
doi: 10.3389/fnins.2019.01381

Parkinson's disease (PD) is a common age-related neurodegenerative disorder with disabling motor symptoms and no available disease modifying treatment. The majority of the PD cases are of unknown etiology, with both genetics and environment playing important roles. Over the past 25 years, however, genetic analysis of patients with familial history of Parkinson's and, latterly, genome wide association studies (GWAS) have provided significant advances in our understanding of the causes of the disease. These genetic insights have uncovered pathways that are affected in both genetic and sporadic forms of PD. These pathways involve oxidative stress, abnormal protein homeostasis, mitochondrial dysfunction, and lysosomal defects. In addition, newly identified PD genes and GWAS nominated genes point toward synaptic changes involving vesicles. This review will highlight the genes that contribute PD risk relating to intracellular vesicle trafficking and their functional consequences. There is still much to investigate on this newly identified and converging pathway of vesicular dynamics and PD, which will aid in better understanding and suggest novel therapeutic strategies for PD patients.

Keywords: Parkinson's disease, genetics, genome wide association studies, vesicular dysfunction, lysosomal dysfunction, alpha-synuclein, leucine-rich repeat kinase 2, Rab proteins

INTRODUCTION

Parkinson's Disease (PD) is a progressive and a debilitating neurodegenerative disorder which usually occurs in people in their sixth decade with an incidence of around 1% (De Lau and Breteler, 2006). The presenting clinical features at diagnosis include bradykinesia as an essential feature, together with resting tremor and rigidity (Gibb and Lees, 1988). Along with and occasionally preceding the motor symptoms are non-motor symptoms such as anosmia, constipation and sleep disturbances can also be observed (Schapira et al., 2017). With the progression of the disease, patients also develop non-motor features including dementia and neuropsychiatric symptoms (Politis et al., 2010). The loss of dopaminergic cells in the *substantia nigra* leading to a deficit of dopamine in the striatum is the cause of the typical motor features (Fearnley and Lees, 1991). Neuropathological characteristics include dopaminergic cell loss and the presence of Lewy bodies (LBs) and dystrophic neurites termed Lewy neurites (LNs) in the *substantia nigra* and other brain regions, the main component of which is fibrillar membrane bound forms of α -synuclein

(Spillantini et al., 1997, 1998). The varied nature of the symptomology is reflected in the wide range of affected brain regions, with pathology spreading from the brainstem to the cortex (Braak et al., 2003). Notably, the LB pathology observed in PD is not restricted to this disorder, and are found in Alzheimer's disease and also in asymptomatic individuals (also termed incidental LB cases) (Parkkinen et al., 2005). Outside of the central nervous system, LBs have also been described in peripheral nerve populations [reviewed in Surmeier and Sulzer (2013)].

Despite the initial clinical description of Parkinson's syndrome more than two centuries ago, to date no disease modifying therapy has been approved for use in humans (Noyce and Bandopadhyay, 2017). Existing therapies are palliative in nature, with dopamine replacement as the main treatment strategy – an approach that does not halt or prevent disease progression. With regard to the underlying etiology, the majority of Parkinson's cases are idiopathic with no discernible specific environmental or genetic cause, however, approximately 5–10% of cases are linked directly to deleterious inherited genetic variants (Reed et al., 2019). Over the past two decades mutations in at least 17 disease segregating genes have been identified [reviewed in Karimi-Moghadam et al. (2018)]. Recent Genome wide association studies (GWAS) have identified further loci across the human genome that are linked to increased lifetime risk for Parkinson's in idiopathic disease (Kia et al., 2019; Nalls et al., 2019). Research into the actions and dysfunctions of the genes and their proteins have highlighted a number of common pathways in PD; affecting mitochondrial dysfunction, autolysosomal dysfunction, oxidative stress, vesicular dysfunction, and abnormal proteostasis (Zhou et al., 2008; Ebrahimi-Fakhari et al., 2012; Cieri et al., 2017). Additionally, PD is also influenced by non-cell-autonomous mechanisms such as cell-to cell transmission of protein aggregates (thought to be driven by a prion-like mechanism) and neuroinflammation (De Virgilio et al., 2016; Rey et al., 2018). In this review we will discuss our current understanding of vesicular dysfunction and abnormal protein handling and their role in the causation of PD, bringing together data from Mendelian forms of PD and GWAS nominated genes (Table 1).

VESICULAR MECHANISMS IN PD PATHOGENESIS

Vesicular mechanisms have been implicated in the pathogenesis of PD by way of several distinct pathways. Within the vesicular system there are several systems of interest, particularly as they apply to potential points of disease propagation and modulation. These points of interest can be seen in **Figure 1**: vesicular fusion (1), endocytosis (2), the *trans* golgi network (TGN) (3) and lysosomal functions (4). At each of these stages in the vesicular process genes have been identified to be familial linked and/or risk factors associated with PD. This not only provides viable evidence for the role of vesicular mechanisms in PD but also genes and proteins which can be investigated at each of these potential points of modulation along the vesicular network.

TABLE 1 | Table showing PD genes and GWAS hits discussed.

Gene loci/ Gene	Inheritance	Protein	Functions
Park1/4 SNCA	AD	Alpha-synuclein	Vesicle fusion/autophagy
Park8/LRRK2	AD	Leucine-rich repeat kinase 2	Autophagy/endosomal functions
Park9/ATP13A2	AR	Cation-transporting ATPase13A2	Lysosomes
Park17/VPS35	AD	Vacuolar protein sorting 35	Endosomal functions
Park19/DNAJC6	AR	DNAJ subfamily C member 13	Endosomal functions
Park20/SYNJ1	AR	Synaptojanin1	Endosomal functions
Park21/DNAJC13	AD	DNAJ subfamily C member 6	Endosomal functions
Park23/VPS13C	AR	Vacuolar protein sorting 13C	Endosomal functions
Unassigned/ Rab39b		Ras like small GTPase	Related to alpha-synuclein
unassigned/GBA		Glucocerebrosidase	Lysosomal functions
GAK*		Cyclin-G associated kinase	Cellular adhesion and trans-golgi network
Rab7L1*		Rab7L1	Links to LRRK2 to trans-golgi network and lysosomal trafficking system
Syt11*		Synaptotagmin11	Autophagy, vesicle fusion

*Denotes GWAS nominated genes. AD, autosomal dominant; AR, autosomal recessive.

At the point of vesicular fusion across membranes, α -synuclein has been implicated. Additionally, synaptojanin1 (SYNJ1), valosin containing proteins and DNAJC proteins have been shown to impact endocytic function. The *trans*-golgi network has also been shown to be impacted by leucine-rich repeat kinase 2 (LRRK2) and Rab proteins. Finally, glucocerebrosidase (GBA), ATP13A2 and synaptotagmin11 (SYT11) affect lysosomal functions. To better understand the possible impact this system may have on the progression of PD, the proteins acting at each point must be further investigated to better appreciate not only their role in the vesicular network, but also how this network can be modulated by therapeutic intervention or used as biomarkers for monitoring disease progression or treatment outcomes.

VESICULAR FUSION

Alpha-Synuclein (α -Synuclein)

A missense mutation (the A53T transversion) in the α -synuclein (SNCA) gene was the first genetic variant to be unambiguously identified as causing PD (Polymeropoulos et al., 1997). Subsequently, further missense mutations (Kruger et al., 1998; Kiely et al., 2013; Zarranz et al., 2014) as well as duplications and triplications of the SNCA gene have been identified indicating that gene dosage is important for the pathogenesis of PD (Singleton et al., 2003; Ibanez et al., 2004). Additionally, polymorphisms in non-coding regions have been identified through GWAS as one of the risk factors for idiopathic




FIGURE 1 | Figure depicting the vesicular process with the points of modulation of PD genes and GWAS nominated genes discussed in this review annotated by (1) vesicular fusion, (2) endocytosis, (3) *trans* golgi network and (4) lysosomes.

PD (Simon-Sanchez et al., 2009) and an untranslated 3' polymorphism increases α -synuclein expression (Soldner et al., 2016), however, how α -synuclein causes dopaminergic (DAergic) neuron degeneration remains unresolved.

Alpha-synuclein is a presynaptic protein which is relatively abundant in the brain (Maroteaux et al., 1988) and endogenous α -synuclein is necessary for DAergic neuron development (Garcia-Reitboeck et al., 2013). Electron microscopy has demonstrated α -synuclein in synaptic vesicles (Tao-Cheng, 2006) and has been shown to be associated with vesicles *in vitro* (Nakamura et al., 2008).

Alpha-synuclein is a natively unfolded protein, but adopts α -helical conformation in presence of membranes (Davidson et al., 1998; Bodner et al., 2009). Structural and biophysical analyses suggest that a membrane bound tetramer version of α -synuclein may represent the functional form of this protein (Bartels et al., 2011; Dettmer et al., 2013), although the physiological relevance of this remains a subject of debate (Fauvet et al., 2012; Theillet et al., 2016). One of the remarkable properties of α -synuclein is its ability to oligomerize, adopt a β pleated sheet conformation and aggregate under non-physiological conditions (Cho et al., 2009). Oligomerization of α -synuclein may contribute to its pathological function and can enhance its aggregation properties, with the majority of pathogenic coding variants increasing the propensity of α -synuclein to aggregate (Guan et al., 2016).

Importantly, aggregated α -synuclein is the most abundant component of Lewy bodies and dystrophic Lewy neurites in PD brain (Spillantini et al., 1998) and is also present in Dementia with Lewy bodies (DLB) brain and can sometimes be present in Alzheimer's disease (AD) brain alongside AD pathology (Matej et al., 2019). Abnormal α -synuclein pathology is also

present in oligodendroglial inclusions – termed glial cytoplasmic inclusions (GCI) in Multiple system atrophy (Ahmed et al., 2012). A recent elegant study using super resolution microscopy has shown that Lewy pathology is interspersed with filaments, dysmorphic organelles together with membraneous structures and vesicles (Shahmoradian et al., 2019). This is important evidence of α -synuclein localization with vesicles and supports the hypothesis that compromised organelle trafficking is a putative driver of PD pathogenesis. These trafficking events could also be playing a part in prodromal PD, thus, making them important early stage points of α -synuclein modulation (Hunn et al., 2015).

A mechanistic link between α -synuclein and vesicular systems was noted as early as 1998 when it was found that, in the case of a familial (A30P) PD mutation (Kruger et al., 1998), the binding of α -synuclein to vesicles was inhibited (Jensen et al., 1998). This implicates the binding of α -synuclein to vesicular membranes in the clearance process providing a possible link between these mechanisms and the accumulation of α -synuclein. Furthermore, studies have shown that α -synuclein disrupts Golgi trafficking network (Cooper et al., 2006). It was also shown that this disruption could be rescued by Rab1, a known modulator of vesicular function (Cooper et al., 2006). Additionally, the reduction of α -synuclein in PD midbrain neurons was shown to restore previously inhibited lysosomal function (Mazzulli et al., 2016). Taken together, these data indicate a potential feedback relationship between α -synuclein and vesicular proteins. It may also provide evidence for the argument that the deposition of α -synuclein occurs further downstream than the disruption of vesicular and lysosomal functions implicating these mechanisms as the catalyst for a large portion of PD pathology.

Further evidence linking α -synuclein and vesicular dynamics was demonstrated by Burré et al., 2010), when oligomeric α -synuclein was shown to promote snare complexes both *in vivo* and *in vitro*, however, it was shown to inhibit membrane fusion. Moreover, binding of calcium to the c-terminus of α -synuclein augmented its lipid-binding property (Lautenschlager et al., 2018) and additionally α -synuclein overexpression facilitated its interaction with VAMP2 and modulate exocytosis (Sun et al., 2019) but whether this occurs in normal physiology remains to be determined. In addition, using cryoelectron tomography, Vargas et al. demonstrated that deletion of all three forms (α, β, γ) of synuclein increases synaptic vesicle (SV) tethering at the active zone but decreases the interlinking of SVs by short connectors (Vargas et al., 2017). It will be important to study how abnormal vesicular dynamics contribute to α -synuclein transition from physiological to abnormal forms which could be relevant for both normal physiology and PD pathology.

ENDOCYTOSIS

Synaptojanin1 (SYNJ1)

Using homozygosity mapping and exome sequencing, a homozygous autosomal recessive mutation in *SYNJ1* gene was identified in a consanguineous family in Italy. The patients manifested Parkinsonism, dystonia motor features together with cognitive decline (Quadri et al., 2013). *SYNJ1* encodes synaptojanin1, a phosphoinositide protein that plays important roles in synaptic vesicle endocytosis (Quadri et al., 2013). More recent studies have reported R258Q and R459P mutations in *SYNJ1* associated with juvenile or early onset PD (Krebs et al., 2013; Kirola et al., 2016), and these mutations impair its phosphatase activity at a mechanistic level. By combining *SYNJ1* heterozygous mutation and *LRRK2 G2019S* mice impaired synaptic vesicle endocytosis was observed in midbrain neurons but not in cortical neurons, thus showing specific defects in dopamine containing neurons (Pan et al., 2017). Knockout of *SYNJ1* in mice results in impaired recycling of synaptic vesicles (Kim et al., 2002), and mice carrying a *SYNJ1 (R258Q)* knock-in mutation present with striking endocytic defects associated with dystrophic axon nerve terminals were seen in the striatum (Cao et al., 2017). It will be important to test whether *SYNJ1* related defects have a role in the pathogenesis of sporadic PD, and to clarify the details of its relationship with *LRRK2* (Islam et al., 2016).

Valosin Containing Proteins (VPS35 and VPS13C)

Through exome sequencing studies, two groups independently discovered heterozygous mutations in the *VPS35* gene linked with late-onset familial PD in 2011 (Vilariño-Güell et al., 2011; Zimprich et al., 2011). Although a number of coding variants have been reported to be associated with Parkinson's, the one clear pathogenic mutation identified is the *D620N* variant, a relatively rare cause of autosomal dominant Parkinson's affecting around 0.4% of all PD cases (Gambardella et al., 2016).

VPS35 is a component of retromer complex, which is involved in intracellular trafficking of proteins (Seaman et al., 1998) and is evolutionarily conserved (Zimprich et al., 2011). In rat cortical neurons, lentivirus-mediated gene transfer of *D620N VPS35* mutation led to increased sensitization of neurons to several stressors; namely MPP+, rotenone and hydrogen peroxide and also increased cell death but no alteration in vesicular localization or abnormal retromer function was noted. Lentiviral overexpression of *D620N* mutation in dopaminergic neurons of the rat lead to neurodegeneration of substantia nigra and axonal damage whereas WT-*VPS35* overexpression produced an intermediate level of neuropathology (Tsika et al., 2014).

A metanalysis of gene expression data from post mortem samples has shown significant downregulation of *VPS35* mRNA levels in PD compared to controls (MacLeod et al., 2013), which was also observed in laser-microdissected PD SN dopamine neurons. Although whether these are reflected at protein levels remains uncertain (Tsika et al., 2014). Further protein level studies with large number of PD and control cases should be a priority. A key caveat to our understanding of how *VPS35* mutations link to Parkinson's is that, to date, no *VPS35* mutation brains have come to post-mortem pathological analysis, and therefore it is not known if *VPS35* PD is a synucleinopathy. It is of interest to note that *VPS35 (D620N)* mutation causes tau pathology in mice (Chen et al., 2019) and its levels are reduced in two primary tauopathies progressive supranuclear palsy and Pick's disease (Vagnozzi et al., 2019).

An recent study by Mir et al. (Mir et al., 2018) demonstrated that *VPS35* has an upstream role regulating *LRRK2s* kinase activity in phosphorylating Rab10. Therefore, modulating *VPS35* actions as a mechanism to suppress *LRRK2* activity could be another approach to a disease modifying strategy in addition to *LRRK2* inhibitors, which are already in Phase1 clinical trial (Hatcher et al., 2017).

VPS13C is the second member of the *VPS* family that has been linked to the pathogenesis of PD. Allelic variations which leads to premature termination of *VPS13C* cause autosomal recessive early onset PD. At post-mortem these cases harbored LBs in the *substantia nigra*, as well as in extra-nigral regions (Lesage et al., 2016). Using yeast models, *VPS13* has been shown to function in the TGN-endosomal cycle in combination with the calcium binding protein Cdc13 (De et al., 2017). The same study (De et al., 2017) also linked *VPS13C* with lipid membranes. Lesage et al. demonstrated reducing *VPS13C* in cells using siRNA resulted in abnormal mitochondrial respiratory rates and also exacerbated Parkin-dependent mitophagy (Lesage et al., 2016). More recently Kumar et al. (Kumar et al., 2018) noted *VPS13*-linked PD mutations links to lipid transport between organelles and endoplasmic reticulum and this can lead to defects in membrane lipid homeostasis. These functions could directly or indirectly associate with vesicular functions and proteostasis dysfunctions in the context of PD pathogenesis.

DNAJC6, DNAJC13, and DNAJC26

DNAJC proteins are part of the heat shock family of proteins which predominantly play a role in stress response (Pauli et al., 1992; Piano et al., 2004). Given this role as well as their action

within the vesicular pathway, their possible involvement in disease has been explored as it relates to the regulation of stress response. Mutations in these genes have been shown to result in disease pathogenesis by way of disrupted protein folding and degradation processes, impaired endosomal transport and vesicular fusion, and the dysfunction of clathrin-mediated trafficking (Roosen et al., 2019).

The two DNAJCs with the most direct link to PD are DNAJC6 (also called auxilin1) and DNAJC26 (also known as GAK or auxilin2, a GWAS nominated gene). Both have been shown to play a role in clathrin-mediated trafficking and have been found to be either known sites of deleterious mutations or risk factors for PD by GWAS (Edvardson et al., 2012; Nalls et al., 2014). Auxilin, which plays a role in endocytosis, has been found to be associated with juvenile onset Parkinsonism (Edvardson et al., 2012; Koroğlu et al., 2013; Elsayed et al., 2016; Nguyen and Krainc, 2018). One possible mechanism through which this occurs was found to be disruption of clathrin-mediated synaptic vesicle endocytosis by LRRK2 phosphorylation of auxilin in DA neurons (Nguyen and Krainc, 2018). Similarly, GAK, a serine/threonine kinase which is structurally analogous to auxilin, has been shown to be involved at the synaptic vesicle membrane level in experimental systems (Kanaoka et al., 1997; Nagle et al., 2016). This however, needs to be validated *in vivo*. Once again, clathrin-mediated vesicle binding is implicated as the mechanism of dysfunction (Nagle et al., 2016). Interestingly, the same study also found a potential link to mitochondrial function, which, given GAK's previously described mechanism of action may indicate a possible role of mitophagy in GAK mediated PD risk. GAK was identified as a putative risk factor locus by a large scale meta-analysis (Nalls et al., 2014). Its expression is ubiquitous, however, lower amounts are expressed in the brain (Roosen et al., 2019). A substrate of GAK phosphorylation is ATP1a3 as demonstrated by chemical genetic identification (Lin et al., 2018) and this is necessary for cargo trafficking. Additionally, GAK has been shown to phosphorylate clathrin heavy chain and AP2 which play a role in vesicle membrane formation and cargo packaging at the cell membrane, respectively, adding further evidence to the role of GAK in the vesicular process (Korolchuk and Banting, 2002; Yabuno et al., 2019). In contrast to DNAJC6/auxilin, GAK is an essential protein during development and adulthood in mice, with GAK knockout being lethal (Lee et al., 2008). It is clearly important to study in more detail the interactions of all the PD risk factors at the level of vesicular functions.

DNAJC13 has also been linked to endosomal function (Girard et al., 2005; Fujibayashi et al., 2007). While cases of PD caused by DNAJC13 mutations are relatively rare, several mutations of the gene have been linked to disease (Gustavsson et al., 2015; Lorenzo-Betancor et al., 2015; Rajput et al., 2015; Ross et al., 2016). After familial cases segregating with DNAJC13 mutations were found, further investigation into the mechanisms of action yielded results which implicated endosomal dysfunction in disease pathogenesis (Vilariño-Güell et al., 2013). The mechanism through which this has been speculated to happen involves the interaction of DNAJC13 with retromer (Popoff et al., 2009). Retromer deals with the targeting and directing

of specific endosomes to the *trans*-Golgi network for recycling (Bonifacino and Hurley, 2008), and provides a link to VPS35 (see above) and a number of other Parkinson's related genes. This implicates DNAJC13 in the regulation of vesicle sorting and thus dysfunction of this protein linked to disease may result in improper sorting of endosomal cargo.

DNAJCs have been implicated in a range of complex neurodegenerative disorders, many of which have a parkinsonian component. Much like the previously discussed proteins, DNAJCs could be potential therapeutic targets for PD. Given the role they play in vesicle docking and fusion they could be an important point of modulation to increase movement of vesicular cargo across membranes in the presence of pathology. However, the protein-protein interactions of many of the DNAJCs may pose challenges for therapeutic targets with GAK being the possible exception, given its role as a kinase making it a more tractable candidate.

TRANS GOLGI NETWORK

LRRK2 (Leucine-Rich-Repeat Kinase 2)

Autosomal dominant LRRK2 mutations were identified in 2008 by two groups (Paisán-Ruiz et al., 2004; Zimprich et al., 2004), with mutations in this gene now recognized as one of the most common genetic contributors to heightened risk of PD affecting different ethnic populations variably, and has also been implicated in sporadic PD (Lesage et al., 2006; Ozelius et al., 2006; Healy et al., 2008; Nalls et al., 2014). The protein product of LRRK2 is a 2527 amino acid/286kDa scaffolding protein with multiple independently acting domains (Gotthardt et al., 2008). LRRK2 protein has ubiquitous expression and is increased in microglia following inflammatory stimuli in mice (Moehle et al., 2012). The large size of the protein and the number of distinct domain structure of the LRRK2 molecule is, however, consistent with the number of functions and the various protein domains is suspected to serve with functions including but not limited to, vesicular trafficking, autophagy and immune response (Rideout and Stefanis, 2014; Wallings et al., 2015). Crucially, LRRK2 associates with membranous structures and vesicles in mammalian brains and recently, integrated-omics analysis identified dysregulation of endocytic pathway in iPS derived DAergic neurons carrying G2019S mutation in the LRRK2 gene (Connor-Robson et al., 2019).

As a member of the ROCO super family, LRRK2 consists of a Ras of complex domain (ROC)/GTPase domain and a kinase domain (KIN) linked by the carboxyl terminal of ROC (COR) (Li et al., 2014). The two active enzymatic domains are at the heart of LRRK2 cellular function, with pathogenic coding variants altering kinase and GTPase function (Alessi and Sammler, 2018). The two enzymatic domains are flanked on either side by several protein-protein interacting domains. Interestingly all of the pathogenic LRRK2 mutations are within the GTPase and kinase domains and they affect the kinase activity. This makes LRRK2 a potentially druggable target, and indeed LRRK2 kinase inhibitors are currently undergoing human trials (Alessi and Sammler, 2018).

Research into the LRRK2 interactome has implicated LRRK2 in cellular trafficking and transport via a number of direct interactors and effector proteins (Manzoni et al., 2015). The link between LRRK2 and lysosomes has been highlighted by the identification of a number of Rab GTPases as substrates for the kinase activity of LRRK2 by proteomic analyses (Steger et al., 2016; Eguchi et al., 2018). Additionally, in a screen for LRRK2 interactors revealed specifically cyclin-G associated kinase (GAK) and Rab7L1/Rab29, a Ras related protein which deals primarily with membrane trafficking, as direct interactors of LRRK2 (Beilina et al., 2014). Rab7L1 was found to be phosphorylated by LRRK2 and is involved in vesicular clearance through the *trans*-Golgi network (Liu et al., 2017). It was shown that LRRK2, phospho-Rab 8/10 together with Rab7L1 help to maintain homeostasis in stressed lysosomes (Eguchi et al., 2018; Jeong et al., 2018) and phosphomutants of Rab proteins at conserved LRRK2 phosphorylation sites induces neurotoxicity and dopaminergic neuron degeneration in mice (Jeong et al., 2018). In human iPS neurons, in wild-type and LRRK2 mutated neurons, it was shown that LRRK2 may be playing a role by phosphorylating auxilin in its clathrin domain at Ser627 which is abolished upon kinase inhibition (Nguyen and Krainc, 2018), and transmission electron microscopy showed decreased synaptic vesicle density in presynaptic nerve terminals of R1441C dopaminergic neurons indicating defective synaptic vesicle endocytosis (Nguyen and Krainc, 2018). This is linked to the accumulation of oxidized dopamine in mutant neurons leading to decreased GBA activity and accrual of α -synuclein (Nguyen and Krainc, 2018). However, the phosphorylation of auxilin by LRRK2 needs to be verified endogenously using site specific phospho-antibody. LRRK2 has also been shown to be linked to the lysosomal pathway and autophagy (Manzoni et al., 2013a) and LRRK2 may phosphorylate EndophilinA to promote autophagy, however, this has not been shown in an endogenous context (Manzoni et al., 2013b; Soukup and Verstreken, 2017). Whilst all these studies provide more compelling evidence for the role of LRRK2 in PD, a key emerging theme of interest is the common mechanism of these LRRK2 interactors. These data tentatively link LRRK2 and vesicular mechanisms although, given the multitude of interactors LRRK2 has been linked to Manzoni et al. (2015) it is difficult to exclude other cellular pathways as being important for disease pathogenesis in LRRK2 mutation cases.

A number of studies highlight a complex link between α -synuclein and LRRK2, and how they might interact in the pathogenesis of PD. It has been shown that LRRK2 alone cannot induce Parkinsonism in a transgenic mouse model but when overexpressed in an α -synuclein transgenic model it does appear to contribute to the acceleration of the disease (Lin et al., 2009). Furthermore, ablation of LRRK2 in this model does appear to offer protection from neurodegeneration to some degree (Lin et al., 2009; Tsika et al., 2014). However, expression of human *R1441CLRRK2* in mice DAergic neurons failed to cause neurodegeneration nor did the mice accumulate abnormal protein inclusions (Tsika et al., 2014). A recent study by Hendersen et al. provides evidence that this may partly derive from LRRK2 acting to potentiate cell to cell

transmission of α -synuclein aggregates, however, it should be noted that not all LRRK2 cases present with the aforementioned aggregates lending to pleiotropic pathology in LRRK2 cases (Henderson et al., 2019; Lewis, 2019). This suggests that there is interplay between α -synuclein and LRRK2, however, the mechanisms through which they interact have remained largely elusive. Additionally, G2019S knock-in mice showed progressive dysfunction of dopamine transporter along with serine-129 phosphorylated α -synuclein accumulation at 12 months of age (Longo et al., 2017). It is possible that the missing functional link may be through vesicular transport wherein α -synuclein and LRRK2 have a dependent relationship as a result of their shared interactions with vesicular proteins.

Rab Proteins

Rab GTPases are members of the Ras superfamily which regulate vesicular mechanisms. These proteins have been shown to play a part in various neurodegenerative diseases through their role in cellular functions including but not limited to endocytosis, vesicle trafficking, vesicle docking, ciliogenesis and interactions in the *trans*-Golgi network (Schimmöller et al., 1998; Rodman and Wandinger-Ness, 2000; Seabra et al., 2002). While the Rab family encompasses roughly 50 proteins with variable functions across the vesicular pathway, 10 have been shown to have a possible relationship to PD either directly or indirectly (Gonçalves et al., 2016; Steger et al., 2016; Chung et al., 2017). The myriad of functions attributed to the Rab proteins and the varied hypothesized routes to pathogenesis in PD can be summarized as the following three pathways: endocytic function and lysosomal stress, ciliogenesis and sonic hedgehog signaling and, lastly the *trans*-Golgi network and endoplasmic reticulum (ER) stress.

With regard to direct evidence of a link between Rab proteins and PD, genetic analysis of three male members of an Australian family with early onset parkinsonism and learning disability revealed a 45 Kb deletion in the Rab39B gene located on the X chromosome, resulting in a complete loss of the protein. In another unrelated Wisconsin kindred, a loss of function missense mutation (c.503C > A) was identified (Wilson et al., 2014). This mutation completely destabilized the protein mimicking a loss of function. Post-mortem analysis of the brain demonstrated widespread LB accumulation along with extensive dopaminergic cell loss in the *substantia nigra*. Iron accumulation, tau immunoreactivity and axonal spheroids were also noted (Wilson et al., 2014). Further to this study, Mata et al. described another X-linked dominant mutation (p.G192R) in the Rab39B gene with reduced penetrance seen in females (Mata et al., 2015). Transient expression of the mutant protein in immortalized cells resulted in its mislocalization (Mata et al., 2015). It is important to note that RAB39b is neuron specific and plays a role in synapse formation and maintenance (Giannandrea et al., 2010). A ShRNA-based screen identified several Rab proteins from endocytic recycling pathway acted as genetic modifiers of α -synuclein secretion, aggregation and toxicity (Gonçalves et al., 2016). Examination of Rab proteins and vesicle recycling components in the context of PD are warranted which might open up novel avenues for therapeutic intervention. While the role of Rab39B in vesicular trafficking is less clear, it has been

shown to play a role in α -synuclein clearance and studies have shown that mutations in this gene can result in PD-like symptoms, intellectual deficits and even early onset PD (Wilson et al., 2014). This can be taken together as a possible pathway to PD through a dysfunction in endosomal processes leading to lysosomal stress, reduced clearance of α -synuclein and ultimately increased α -synuclein deposition.

A number of Rab proteins (Rab8b, Rab11a, and Rab13) have impact on α -synuclein clearance which can have consequences on α -synuclein aggregation (Gonçalves et al., 2016). Similarly, Rab8A has also been shown to play a role in membrane trafficking and clearance as well as protein transport (Chung et al., 2017). Further evidence for the role of Rab8A in development and pathogenesis comes as studies have shown that LRRK2 phosphorylation of Rab8A can cause centrosomal defects and thus cause widespread effects on neurite growth and migration (Madero-Pérez et al., 2018a).

Additionally, Rab proteins are associated in cilia formation and ciliogenesis is implicated in PD pathogenesis. In this regard, LRRK2 R1441C mice show defects in cilia in their brains and LRRK2 kinase activity can block primary cilia formation in cultured cells with phosphorylation of Rab10 acting as a negative regulator in this context (Dhekne et al., 2018). Ciliary signaling is pertinent in olfactory functions (Dhekne et al., 2018) and anosmia is one of the first symptoms of PD. Holistically, this paints a compelling picture of the role of Rabs in neuronal development and how disruption of these pathways both in development and adulthood may lead to PD pathogenesis.

Lastly, disruption of the ER and *trans*-Golgi network have also been found to lead to PD-like pathology. Rab7L1 (also called Rab29) is not only another LRRK2 interactor but also a candidate for the PARK16 locus (Nalls et al., 2014; Steger et al., 2016). Further exploration of the interaction of LRRK2 and Rab7L1 in PD implies that their joint function has primarily to do with sorting through both the Golgi apparatus and lysosomal systems (MacLeod et al., 2013). One possible mechanism for this dysfunction is a change in Golgi morphology mediated by LRRK2 phosphorylation of Rab7L1 (Fujimoto et al., 2018). Furthermore, Rab7L1 promotes recruitment of LRRK2 to the *trans*-Golgi network as well as LRRK2 autophosphorylation thus implicating a malignant feedback relationship between LRRK2 and Rab7L1 in the presence of pathogenic LRRK2 mutations (Liu et al., 2017). Rab7L1 has also been shown to play a role in lysosomal homeostasis along with the aforementioned Rab8A and Rab10 (Eguchi et al., 2018). It was proposed that the recruitment of these Rabs onto enlarged lysosomes ultimately promoted lysosomal secretion and inhibited further enlargement (Eguchi et al., 2018). This stabilizing function was mediated by the recruitment of LRRK2 and Rab7L1 from the Golgi onto the stressed lysosomes placing Rab7L1 further upstream on this pathway than Rab8A and Rab10 even as they serve a similar regulatory function (Eguchi et al., 2018). This is further confirmed by the finding that the centrosomal deficits caused by Rab8A phosphorylation by LRRK2 as it was recruited on to the Golgi by Rab7L1 (Madero-Pérez et al., 2018b). This taken together would indicate that relocalization of LRRK2 mediated by Rab7L1 may result in many of the previously discussed deleterious interactions with Rabs

and other yet unknown effectors further downstream. Studies to unveil the mechanistic details of Rab protein functioning and its downstream consequences as seen by its interaction with RIPL1 (Dhekne et al., 2018) could open new therapeutic avenues for PD treatment.

LYSOSOMAL FUNCTION

GBA (Glucocerebrosidase)

Gaucher's disease (GD), inherited in autosomal recessive pattern results from the deficiency of the enzyme GBA and is the most common lysosomal storage disease (Tsuji et al., 1987; Hruska et al., 2008). In addition to multisystem lysosomal storage dysfunction, a proportion of patients with neuropathic GD presenting with the clinical features of PD, and GD associated mutations in the heterozygous state act as a strong risk factor for idiopathic PD (Sidransky et al., 2009), and to date more than 300 GBA mutations have been reported. In addition, GWA studies have identified GBA variants as risk factors of PD (Simon-Sanchez et al., 2009; Blauwendraat et al., 2018). In normal physiology, GBA cleaves off glucose for use in lysosomal metabolic processes, thus, the dysfunction of this enzyme can lead to overall lysosomal dysfunction (Do et al., 2019). Crucially, GBA-PD and sporadic PD patients show a loss in GBA activity and GBA levels (Gegg et al., 2012; Murphy et al., 2014).

Sardi et al. (Sardi et al., 2011) provided evidence that a mouse model of GBA (D409V/D409V) showed characteristics of synucleinopathies including progressive accumulation of proteinase K resistant α -synuclein accumulation and cognitive deficits. Additionally, exogenous administration using adeno associated virus containing recombinant GBA can overcome pathological features in mice (Sardi et al., 2011). In another study, Glucosylceramide (GlcCer), the GBA substrate, control the formation of α -synuclein assemblies in primary neurons and in human iPS neurons leading to neurodegeneration (Mazzulli et al., 2011). They also suggested a bidirectional process between accumulation of toxic α -synuclein species and GCase levels which may lead to self-propagation of disease (Mazzulli et al., 2011). GBA1 KO mouse embryonic fibroblasts and in-patient derived fibroblasts with GBA1 mutation affects lysosomal recycling resulting in Rab7 accumulation in lysosomes (Magalhaes et al., 2016) while GBA KO in drosophila resulted in abnormal lysosomal pathology, mTOR activity was downregulated and rapamycin ameliorated the lifespan of flies (Bai et al., 2015; Kinghorn et al., 2016). It is important to note that all of the GBA cases that have been examined at post-mortem harbor α -synuclein pathology (Schneider and Alcalay, 2017).

ATP13A2 and Synaptotagmin 11 (SYT11)

Autosomal recessive mutations in ATP13A2 cause an early onset parkinsonian syndrome (kufor rakeb syndrome, KRS) and have also been linked to neuronal ceroid lipofuscinosis (Ramirez et al., 2006; Crosiers et al., 2011). It belongs to the 5P-type subfamily of ATPase and is a lysosomal transmembrane protein (Ramirez et al., 2006). Loss of ATP13A2 leads to instability of the lysosomal membrane leading to impaired lysosomal function

and proteolysis which could result from imbalance of divalent cation levels (Dehay et al., 2012; Tofaris, 2012). Evidence from one brain studied at autopsy with mutation in *ATP13A2*, has shown absence of LBs but presence of lipofuscinosis in cortex, basal nuclei and cerebellum and retina (Bras et al., 2012). One possibility is that the disruption of divalent cation homeostasis within neurons could be responsible for lysosomal defects and neurodegeneration, however, the precise mechanisms underpinning disease are, to date, unclear (Usenovic et al., 2012; Lubbe et al., 2016).


Synaptotagmin 11 (*SYT11*), also a GWAS nominated gene, is a protein which deals largely with vesicular fusion with the membrane and exocytosis (Südhof, 2012; Nalls et al., 2014). Much like *ATP13A2*, *SYT11* regulates autophagy by way of modulating lysosomal function (Bento et al., 2016). It has been found that not only do decreased levels of *SYT11* induce lysosomal dysfunction but it is required for parkin-linked dysfunction in PD (Bento et al., 2016; Wang et al., 2018). Furthermore, a recent study has affirmed the relevance of the originally found GWA locus for *GBA*, the *GBA-SYT11* locus, implicating a link between *SYT11* and other lysosomal PD genes such as *GBA* (Blauwendraat et al., 2018).

PD AS A DYSFUNCTION OF VESICULAR MECHANISMS

The regulation of intracellular vesicles formation and trafficking is central to cellular function, with disruption of the pathways involved in these processes having serious consequences for health. Evidence from human genetics and model systems support a key role for vesicular biology in the etiology of PD, stretching across a range of organelles and cell types.

Given the complex interactions between vesicular proteins and the role of multiple pathways and networks in maintaining vesicular homeostasis, it is becoming clear that disruption at a number of points in vesicle regulation in the human brain can result in neurodegeneration and the development of parkinsonism. Importantly this implies that many of the genes, protein interactions and pathways discussed in this review may be valid pathological origins for PD and is summarized in **Figure 2**. The range of cellular events impacted by vesicle trafficking, coupled with the array of cell types and brain regions involved, could account for the wide variety of possible genetic offenders and the variability of disease profile within patient cohorts. Studies have begun to focus on this more dynamic perspective, describing the pathological presentation in terms of affected pathways rather than singular genes and proteins as what would amount to organelles crowded with non-functioning vesicles and vesicular proteins (Shahmoradian et al., 2018). It is clear that to use these insights into vesicular trafficking and the pathogenesis of Parkinson's in a meaningful way to inform the development of novel therapeutics, the proteins which work within these pathways must be better understood and, furthermore, the mechanisms by which they interact with one another must be explored.

As seen by the graphical representation of vesicular system shown in **Figure 1**, there are many possible points of systemic deficit but also many points of potential modulation. To tease out these possible therapeutic targets an expansion of the interactors of each these proteins as well as their isomeric forms would be necessary. Given that a large portion of what would appear to be the targets further upstream of α -synuclein, such as the previously discussed *Rab7L1*, *GAK*, and *ATP13A2*, are most functionally active along the golgi- lysosomal axis further



exploration of their interactors and regulators would clarify the role of this system in pathogenesis.

CONCLUSION AND FUTURE PERSPECTIVE

Our understanding of the genetic landscape of PD has expanded rapidly over the past two decades through increased identification of Mendelian inheritance genes and the nomination of risk loci through GWA studies. The challenge for researchers is to translate the risk genes identified using GWAS, integrate these with Mendelian genes and move toward unraveling novel pathways for disease modification treatments. Some groups have already begun deciphering the points of interaction of some of the risk factors as being at the synapses (Nguyen and Krainc, 2018; Wang et al., 2018) which could well be a starting point of disease pathogenesis and could occur long before clinical symptoms appear. Based upon these advances, our understanding of the disease processes that contribute to PD is maturing. Further studies involving other risk genes are highly warranted at this time point.

Clues from neuropathology studies suggest that PD is a multifactorial disorder, with α -synuclein spread occurring in a systematic way from one brain region to another which are neuroanatomically connected (Braak et al., 2003). The prion-like propagation of α -synuclein pathology may be an important event in disease pathogenesis (Luk et al., 2012; Peng et al., 2018). A systematic approach is now needed to weave together the potential risk factors involving the entire vesicular pathway and ascertain a temporal sequence of events. Importantly, the key will be in understanding how these factors contribute to aggregation of α -synuclein, the major pathological player in sporadic PD and also in several of the Mendelian forms

of the disease (Schneider and Alcalay, 2017). Such studies should also foster discoveries of early diagnostic biomarker tools, which remains another critical unmet need. Given that the bulk of neuronal loss is pre symptomatic, screenable biomarkers derived from investigations of vesicular proteins may form a basis for opportunities for early treatment with existing therapies and the opportunity to stem novel treatments (Miller and O'Callaghan, 2015).

Another important issue to consider is whether the interactions occur in glial cells vs. neuronal cell types, which may be more relevant for LRRK2 as it is highly expressed in immune cells (Kia et al., 2019). It will be important to identify key facilitators and aggravators of PD (Johnson et al., 2019) in order to develop treatment for patients at the prodromal stage. It will also be critical to tease out the granular details of vesicular pathway disruption at a cellular level, and to distinguish between primary events and secondary sequelae. This will, in turn, provide the foundations for continuing drug development efforts for Parkinson's.

AUTHOR CONTRIBUTIONS

KE made the first draft of the manuscript. PL and RB provided the expert comments and suggestions, and wrote parts of the review. All authors approved the final version of the manuscript.

FUNDING

KE was supported by the W. A. Dart Memorial Scholarship and the Government Scholarship of the Cayman Islands. PL was supported by the MRC Programme grant MR/N026004/1. RB was supported by the Reta Lila Weston Institute, UCL.

REFERENCES

- Ahmed, Z., Asi, Y., Sailer, A., Lees, A., Houlden, H., Revesz, T., et al. (2012). The neuropathology, pathophysiology and genetics of multiple system atrophy. *Neuropathol. Appl. Neurobiol.* 38, 4–24. doi: 10.1111/j.1365-2990.2011.01234.x
- Alessi, D. R., and Sammler, E. (2018). LRRK2 kinase in Parkinson's disease. *Science* 360, 36–37.
- Bai, X., Wey, M. C.-Y., Fernandez, E., Hart, M. J., Gelfond, J., Bokov, A. F., et al. (2015). Rapamycin improves motor function, reduces 4-hydroxynonenal adducted protein in brain, and attenuates synaptic injury in a mouse model of synucleinopathy. *Pathobiol. Aging Age-Related Dis.* 5:28743. doi: 10.3402/pba.v5.28743
- Bartels, T., Choi, J. G., and Selkoe, D. J. (2011). α -Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. *Nature* 477, 107–110. doi: 10.1038/nature10324
- Beilina, A., Rudenko, I. N., Kaganovich, A., Civiero, L., Chau, H., Kalia, S. K., et al. (2014). Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. *Proc. Natl. Acad. Sci. U.S.A.* 111, 2626–2631. doi: 10.1073/pnas.1318306111
- Bento, C. F., Ashkenazi, A., Jimenez-Sanchez, M., and Rubinsztein, D. C. (2016). The Parkinson's disease-associated genes ATP13A2 and SYT11 regulate autophagy via a common pathway. *Nat. Commun.* 7:11803.
- Blauwendraat, C., Bras, J. M., Nalls, M. A., Lewis, P. A., Hernandez, D. G., Singleton, A. B., et al. (2018). Coding variation in GBA explains the majority of the SYT11-GBA Parkinson's disease GWAS locus. *Move. Disord.* 33:1821. doi: 10.1002/mds.103
- Bodner, C. R., Dobson, C. M., and Bax, A. (2009). Multiple tight phospholipid-binding modes of α -synuclein revealed by solution NMR spectroscopy. *J. Mol. Biol.* 390, 775–790. doi: 10.1016/j.jmb.2009.05.066
- Bonifacio, J. S., and Hurley, J. H. (2008). Retromer. *Curr. Opin. Cell Biol.* 20, 427–436. doi: 10.1016/j.ceb.2008.03.009
- Braak, H., Del Tredici, K., Rüb, U., De Vos, R. A., Steur, E. N. J., and Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiol. Aging* 24, 197–211. doi: 10.1016/s0197-4580(02)00065-9
- Bras, J., Verloes, A., Schneider, S. A., Mole, S. E., and Guerreiro, R. J. (2012). Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis. *Hum. Mol. Genet.* 21, 2646–2650. doi: 10.1093/hmg/dds089
- Burré, J., Sharma, M., Tsetsenis, T., Buchman, V., Etherton, M. R., and Südhof, T. C. (2010). α -Synuclein promotes SNARE-complex assembly *in vivo* and *in vitro*. *Science* 329, 1663–1667. doi: 10.1126/science.1195227
- Cao, M., Wu, Y., Ashrafi, G., McCartney, A. J., Wheeler, H., Bushong, E. A., et al. (2017). Parkinson Sac domain mutation in synaptotagmin 1 impairs clathrin uncoating at synapses and triggers dystrophic changes in dopaminergic axons. *Neuron* 93, 882.e5–896.e5. doi: 10.1016/j.neuron.2017.01.019
- Chen, X., Kordich, J. K., Williams, E. T., Levine, N., Cole-Strauss, A., Marshall, L., et al. (2019). Parkinson's disease-linked D620N VPS35 knockin mice manifest

- tau neuropathology and dopaminergic neurodegeneration. *Proc. Natl. Acad. Sci. U.S.A.* 116, 5765–5774. doi: 10.1073/pnas.1814909116
- Cho, M. K., Nodet, G., Kim, H. Y., Jensen, M. R., Bernado, P., Fernandez, C. O., et al. (2009). Structural characterization of α -synuclein in an aggregation prone state. *Protein Sci.* 18, 1840–1846. doi: 10.1002/pro.194
- Chung, C. Y., Khurana, V., Yi, S., Sahni, N., Loh, K. H., Auluck, P. K., et al. (2017). In situ peroxidase labeling and mass-spectrometry connects α -synuclein directly to endocytic trafficking and mRNA metabolism in neurons. *Cell Syst.* 4, 242.e4–250.e4. doi: 10.1016/j.cels.2017.01.002
- Cieri, D., Brini, M., and Cali, T. (2017). Emerging (and converging) pathways in Parkinson's disease: keeping mitochondrial wellness. *Biochem. Biophys. Res. Commun.* 483, 1020–1030. doi: 10.1016/j.bbrc.2016.08.153
- Connor-Robson, N., Booth, H., Martin, J. G., Gao, B., Li, K., Doig, N., et al. (2019). An integrated transcriptomics and proteomics analysis reveals functional endocytic dysregulation caused by mutations in LRRK2. *Neurobiol. Dis.* 127, 512–526. doi: 10.1016/j.nbd.2019.04.005
- Cooper, A. A., Gitler, A. D., Cashikar, A., Haynes, C. M., Hill, K. J., Bhullar, B., et al. (2006). α -Synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. *Science* 313, 324–328. doi: 10.1126/science.1129462
- Crosiers, D., Ceulemans, B., Meeus, B., Nuytemans, K., Pals, P., Van Broeckhoven, C., et al. (2011). Juvenile dystonia-parkinsonism and dementia caused by a novel ATP13A2 frameshift mutation. *Parkinson. Relat. Disord.* 17, 135–138. doi: 10.1016/j.parkreldis.2010.10.011
- Davidson, W. S., Jonas, A., Clayton, D. F., and George, J. M. (1998). Stabilization of α -synuclein secondary structure upon binding to synthetic membranes. *J. Biol. Chem.* 273, 9443–9449. doi: 10.1074/jbc.273.16.9443
- De, M., Oleskie, A. N., Ayyash, M., Dutta, S., Mancour, L., Abazeed, M. E., et al. (2017). The Vps13p–Cdc31p complex is directly required for TGN late endosome transport and TGN homotypic fusion. *J. Cell Biol.* 216, 425–439. doi: 10.1083/jcb.201606078
- De Lau, L. M., and Breteler, M. M. (2006). Epidemiology of Parkinson's disease. *Lancet Neurol.* 5, 525–535.
- De Virgilio, A., Greco, A., Fabbri, G., Inghilleri, M., Rizzo, M. I., Gallo, A., et al. (2016). Parkinson's disease: autoimmunity and neuroinflammation. *Autoimmun. Rev.* 15, 1005–1011. doi: 10.1016/j.autrev.2016.07.022
- Dehay, B., Ramirez, A., Martinez-Vicente, M., Perier, C., Canon, M. H., Doudnikoff, E., et al. (2012). Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. *Proc. Natl. Acad. Sci. U.S.A.* 109, 9611–9616. doi: 10.1073/pnas.1112368109
- Dettmer, U., Newman, A. J., Luth, E. S., Bartels, T., and Selkoe, D. (2013). In vivo cross-linking reveals principally oligomeric forms of α -synuclein and β -synuclein in neurons and non-neural cells. *J. Biol. Chem.* 288, 6371–6385. doi: 10.1074/jbc.M112.403311
- Dhekne, H. S., Yanatori, I., Gomez, R. C., Tonelli, F., Diez, F., Schüle, B., et al. (2018). A pathway for Parkinson's Disease LRRK2 kinase to block primary cilia and Sonic hedgehog signaling in the brain. *eLife* 7:e40202. doi: 10.7554/eLife.40202
- Do, J., McKinney, C., Sharma, P., and Sidransky, E. (2019). Glucocerebrosidase and its relevance to Parkinson disease. *Mol. Neurodegen.* 14:36. doi: 10.1186/s13024-019-0336-2
- Ebrahimi-Fakhari, D., Wahlster, L., and McLean, P. J. (2012). Protein degradation pathways in Parkinson's disease: curse or blessing. *Acta Neuropathol.* 124, 153–172. doi: 10.1007/s00401-012-1004-6
- Edvardson, S., Cinnamon, Y., Ta-Shma, A., Shaag, A., Yim, Y.-I., Zenvirt, S., et al. (2012). A deleterious mutation in DNAJC6 encoding the neuronal-specific clathrin-uncoating co-chaperone auxilin, is associated with juvenile parkinsonism. *PLoS One* 7:e36458. doi: 10.1371/journal.pone.0036458
- Eguchi, T., Kuwahara, T., Sakurai, M., Komori, T., Fujimoto, T., Ito, G., et al. (2018). LRRK2 and its substrate Rab GTPases are sequentially targeted onto stressed lysosomes and maintain their homeostasis. *Proc. Natl. Acad. Sci. U.S.A.* 115, E9115–E9124. doi: 10.1073/pnas.1812196115
- Elsayed, L., Drouet, V., Usenko, T., Mohammed, I., Hamed, A., Elseed, M., et al. (2016). A novel nonsense mutation in DNAJC6 expands the phenotype of autosomal-recessive juvenile-onset Parkinson's disease. *Ann. Neurol.* 79, 335–337. doi: 10.1002/ana.24591
- Fauvet, B., Mbefo, M. K., Fares, M. B., Desobry, C., Michael, S., Ardah, M. T., et al. (2012). α -Synuclein in central nervous system and from erythrocytes, mammalian cells, and *Escherichia coli* exists predominantly as disordered monomer. *J. Biol. Chem.* 287, 15345–15364. doi: 10.1074/jbc.M111.318949
- Fearnley, J. M., and Lees, A. J. (1991). Ageing and Parkinson's disease: substantia nigra regional selectivity. *Brain* 114(Pt 5), 2283–2301. doi: 10.1093/brain/114.5.2283
- Fujibayashi, A., Taguchi, T., Misaki, R., Ohtani, M., Dohmae, N., Takio, K., et al. (2007). Human RME-8 is involved in membrane trafficking through early endosomes. *Cell Struct. Funct.* 33, 35–50. doi: 10.1247/csf.07045
- Fujimoto, T., Kuwahara, T., Eguchi, T., Sakurai, M., Komori, T., and Iwatsubo, T. (2018). Parkinson's disease-associated mutant LRRK2 phosphorylates Rab7L1 and modifies trans-Golgi morphology. *Biochem. Biophys. Res. Commun.* 495, 1708–1715. doi: 10.1016/j.bbrc.2017.12.024
- Gambardella, S., Biagioni, F., Ferese, R., Busceti, C. L., Frati, A., Novelli, G., et al. (2016). Vacuolar protein sorting genes in Parkinson's disease: a re-appraisal of mutations detection rate and neurobiology of disease. *Front. Neurosci.* 10:532. doi: 10.3389/fnins.2016.00532
- Garcia-Reitboeck, P., Anichtchik, O., Dalley, J. W., Ninkina, N., Tofaris, G. K., Buchman, V. L., et al. (2013). Endogenous α -synuclein influences the number of dopaminergic neurons in mouse substantia nigra. *Exp. Neurol.* 248, 541–545. doi: 10.1016/j.expneurol.2013.07.015
- Gegg, M. E., Burke, D., Heales, S. J., Cooper, J. M., Hardy, J., Wood, N. W., et al. (2012). Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. *Ann. Neurol.* 72, 455–463. doi: 10.1002/ana.23614
- Giannandrea, M., Bianchi, V., Mignogna, M. L., Sirri, A., Carrabino, S., D'Elia, E., et al. (2010). Mutations in the small GTPase gene RAB39B are responsible for X-linked mental retardation associated with autism, epilepsy, and macrocephaly. *Am. J. Hum. Genet.* 86, 185–195. doi: 10.1016/j.ajhg.2010.01.011
- Gibb, W. R., and Lees, A. J. (1988). The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. *J. Neurol. Neurosurg. Psychiatry* 51, 745–752. doi: 10.1136/jnnp.51.6.745
- Girard, M., Poupon, V., Blondeau, F., and McPherson, P. S. (2005). The DnaJ-domain protein RME-8 functions in endosomal trafficking. *J. Biol. Chem.* 280, 40135–40143. doi: 10.1074/jbc.M505036200
- Gonçalves, S. A., Macedo, D., Raquel, H., Simões, P. D., Giorgini, F., Ramalho, J. S., et al. (2016). shRNA-based screen identifies endocytic recycling pathway components that act as genetic modifiers of α -synuclein aggregation, secretion and toxicity. *PLoS Genet.* 12:e1005995. doi: 10.1371/journal.pgen.1005995
- Gotthardt, K., Weyand, M., Kortholt, A., Van Haastert, P. J., and Wittinghofer, A. (2008). Structure of the Roc–COR domain tandem of *C. tepidum*, a prokaryotic homologue of the human LRRK2 Parkinson kinase. *EMBO J.* 27, 2239–2249. doi: 10.1038/emboj.2008.150
- Guan, M., Li, J., Jia, Q., Ge, J., Chen, D., Zhou, Y., et al. (2016). A versatile and clearable nanocarbon theranostic based on carbon dots and gadolinium metallofullerene nanocrystals. *Adv. Healthcare Mater.* 5, 2283–2294. doi: 10.1002/adhm.201600402
- Gustavsson, E. K., Trinh, J., Guella, I., Vilariño-Güell, C., Appel-Cresswell, S., Stoessl, A. J., et al. (2015). DNAJC13 genetic variants in parkinsonism. *Mov. Disord.* 30, 273–278. doi: 10.1002/mds.26064
- Hatcher, J. M., Choi, H. G., Alessi, D. R., and Gray, N. S. (2017). “Small-molecule inhibitors of LRRK2,” in *Leucine-Rich Repeat Kinase 2 (LRRK2)*, ed. H. Rideout (Cham: Springer), 241–264. doi: 10.1007/978-3-319-49969-7_13
- Healy, D. G., Falchi, M., O'Sullivan, S. S., Bonifati, V., Durr, A., Bressman, S., et al. (2008). Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. *Lancet Neurol.* 7, 583–590. doi: 10.1016/S1474-4422(08)70117-0
- Henderson, M. X., Cornblath, E. J., Darwich, A., Zhang, B., Brown, H., Gathagan, R. J., et al. (2019). Spread of α -synuclein pathology through the brain connectome is modulated by selective vulnerability and predicted by network analysis. *Nat. Neurosci.* 22:1248. doi: 10.1038/s41593-019-0457-5
- Hruska, K. S., LaMarca, M. E., Scott, C. R., and Sidransky, E. (2008). Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (*GBA*). *Hum. Mutat.* 29, 567–583. doi: 10.1002/humu.20676
- Hunn, B. H., Cragg, S. J., Bolam, J. P., Spillantini, M.-G., and Wade-Martins, R. (2015). Impaired intracellular trafficking defines early Parkinson's disease. *Trends Neurosci.* 38, 178–188. doi: 10.1016/j.tins.2014.12.009

- Ibanez, P., Bonnet, A., Debarges, B., Lohmann, E., Tison, F., Agid, Y., et al. (2004). Causal relation between α -synuclein locus duplication as a cause of familial Parkinson's disease. *Lancet* 364, 1169–1171. doi: 10.1016/s0140-6736(04)17104-3
- Islam, M. S., Nolte, H., Jacob, W., Ziegler, A. B., Putz, S., Grosjean, Y., et al. (2016). Human R1441C LRRK2 regulates the synaptic vesicle proteome and phosphoproteome in a *Drosophila* model of Parkinson's disease. *Hum. Mol. Genet.* 25, 5365–5382. doi: 10.1093/hmg/ddw352
- Jensen, P. H., Nielsen, M. S., Jakes, R., Dotti, C. G., and Goedert, M. (1998). Binding of α -synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. *J. Biol. Chem.* 273, 26292–26294. doi: 10.1074/jbc.273.41.26292
- Jeong, G. R., Jang, E.-H., Bae, J. R., Jun, S., Kang, H. C., Park, C.-H., et al. (2018). Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration. *Mol. Neurodegen.* 13:8. doi: 10.1186/s13024-018-0240-1
- Johnson, M. E., Stecher, B., Labrie, V., Brundin, L., and Brundin, P. (2019). Triggers, facilitators, and aggravators: redefining Parkinson's disease pathogenesis. *Trends Neurosci.* 42, 4–13. doi: 10.1016/j.tins.2018.09.007
- Kanaoka, Y., Kimura, S. H., Okazaki, I., Ikeda, M., and Nojima, H. (1997). GAK: a cyclin G associated kinase contains a tensin/auxilin-like domain 1. *FEBS Lett.* 402, 73–80. doi: 10.1016/s0014-5793(96)01484-6
- Karimi-Moghadam, A., Charsouei, S., Bell, B., and Jabalameli, M. R. (2018). Parkinson disease from mendelian forms to genetic susceptibility: new molecular insights into the neurodegeneration process. *Cell. Mol. Neurobiol.* 38, 1153–1178. doi: 10.1007/s10571-018-0587-4
- Kia, D. A., Zhang, D., Guelfi, S., Manzoni, C., Hubbard, L., Reynolds, R. H., et al. (2019). Integration of eQTL and Parkinson's disease GWAS data implicates 11 disease genes. *bioRxiv[Preprints]*
- Kiely, A. P., Asi, Y. T., Kara, E., Limousin, P., Ling, H., Lewis, P., et al. (2013). α -Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? *Acta Neuropathol.* 125, 753–769. doi: 10.1007/s00401-013-1096-7
- Kim, W. T., Chang, S., Daniell, L., Cremona, O., Di Paolo, G., and De Camilli, P. (2002). Delayed reentry of recycling vesicles into the fusion-competent synaptic vesicle pool in synaptotagmin 1 knockout mice. *Proc. Natl. Acad. Sci. U.S.A.* 99, 17143–17148. doi: 10.1073/pnas.222657399
- Kinghorn, K. J., Grönke, S., Castillo-Quan, J. I., Woodling, N. S., Li, L., Sirka, E., et al. (2016). A *Drosophila* model of neuronopathic Gaucher disease demonstrates lysosomal-autophagic defects and altered mTOR signalling and is functionally rescued by rapamycin. *J. Neurosci.* 36, 11654–11670. doi: 10.1523/jneurosci.4527-15.2016
- Kirolo, L., Behari, M., Shishir, C., and Thelma, B. K. (2016). Identification of a novel homozygous mutation Arg459Pro in SYNJ1 gene of an Indian family with autosomal recessive juvenile Parkinsonism. *Parkinson. Relat. Disord.* 31, 124–128. doi: 10.1016/j.parkreldis.2016.07.014
- Köroğlu, Ç., Baysal, L., Cetinkaya, M., Karasoy, H., and Tolun, A. (2013). DNAJC6 is responsible for juvenile parkinsonism with phenotypic variability. *Parkinson. Relat. Disord.* 19, 320–324. doi: 10.1016/j.parkreldis.2012.11.006
- Korolchuk, V. I., and Banting, G. (2002). CK2 and GAK/auxilin2 are major protein kinases in clathrin-coated vesicles. *Traffic* 3, 428–439. doi: 10.1034/j.1600-0854.2002.30606.x
- Krebs, C. E., Karkheiran, S., Powell, J. C., Cao, M., Makarov, V., Darvish, H., et al. (2013). The Sac1 domain of SYNJ1 identified mutated in a family with early-onset progressive Parkinsonism with generalized seizures. *Hum. Mutat.* 34, 1200–1207. doi: 10.1002/humu.22372
- Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., et al. (1998). Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. *Nat. Genet.* 18, 106–108. doi: 10.1038/ng0298-106
- Kumar, N., Leonzino, M., Hancock-Cerutti, W., Horenkamp, F. A., Li, P., Lees, J. A., et al. (2018). VPS13A and VPS13C are lipid transport proteins differentially localized at ER contact sites. *J. Cell Biol.* 217, 3625–3639. doi: 10.1083/jcb.201807019
- Lautenschlager, J., Stephens, A. D., Fusco, G., Strohl, F., Curry, N., Zacharopoulou, M., et al. (2018). C-terminal calcium binding of alpha-synuclein modulates synaptic vesicle interaction. *Nat. Commun.* 9:712. doi: 10.1038/s41467-018-03111-4
- Lee, D.-W., Zhao, X., Yim, Y.-I., Eisenberg, E., and Greene, L. E. (2008). Essential role of cyclin-G-associated kinase (auxilin-2) in developing and mature mice. *Mol. Biol. Cell* 19, 2766–2776. doi: 10.1091/mbc.E07-11-1115
- Lesage, S., Drouet, V., Majounie, E., Deramecourt, V., Jacoupy, M., Nicolas, A., et al. (2016). Loss of VPS13C function in autosomal-recessive Parkinsonism causes mitochondrial dysfunction and increases PINK1/Parkin-dependent mitophagy. *Am. J. Hum. Genet.* 98, 500–513. doi: 10.1016/j.ajhg.2016.01.014
- Lesage, S., Dürr, A., Tazir, M., Lohmann, E., Leutenegger, A.-L., Janin, S., et al. (2006). LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. *N. Engl. J. Med.* 354, 422–423.
- Lewis, P. A. (2019). Leucine rich repeat kinase 2: a paradigm for pleiotropy. *J. Physiol.* 597, 3511–3521. doi: 10.1113/JP276163
- Li, B., Ge, P., Murray, K. A., Sheth, P., Zhang, M., Nair, G., (2018). Cryo-EM of full-length α -synuclein reveals fibril polymorphs with a common structural kernel. *Nat. Commun.* 9:3609. doi: 10.1038/s41467-018-05971-2
- Li, J.-Q., Tan, L., and Yu, J.-T. (2014). The role of the LRRK2 gene in Parkinsonism. *Mol. Neurodegen.* 9:47. doi: 10.1186/1750-1326-9-47
- Lin, A. W., Gill, K. K., Castañeda, M. S., Matucci, I., Eder, N., Claxton, S., et al. (2018). Chemical genetic identification of GAK substrates reveals its role in regulating Na⁺/K⁺-ATPase. *Life Sci. Alliance* 1:e201800118. doi: 10.26508/lsa.201800118
- Lin, X., Parisiadou, L., Gu, X.-L., Wang, L., Shim, H., Sun, L., et al. (2009). Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant α -synuclein. *Neuron* 64, 807–827. doi: 10.1016/j.neuron.2009.11.006
- Liu, Z., Bryant, N., Kumaran, R., Beilina, A., Abeliovich, A., Cookson, M. R., et al. (2017). LRRK2 phosphorylates membrane-bound Rabs and is activated by GTP-bound Rab7L1 to promote recruitment to the trans-Golgi network. *Hum. Mol. Genet.* 27, 385–395. doi: 10.1093/hmg/ddx410
- Longo, F., Mercatelli, D., Novello, S., Arcuri, L., Brugnoli, A., Vincenzi, F., et al. (2017). Age-dependent dopamine transporter dysfunction and Serine129 phospho- α -synuclein overload in G2019S LRRK2 mice. *Acta Neuropathol. Commun.* 5:22. doi: 10.1186/s40478-017-0426-8
- Lorenzo-Betancor, O., Ogaki, K., Soto-Ortolaza, A. I., Labbé, C., Walton, R. L., Strongosky, A. J., et al. (2015). DNAJC13 p. Asn855Ser mutation screening in Parkinson's disease and pathologically confirmed Lewy body disease patients. *Eur. J. Neurol.* 22, 1323–1325. doi: 10.1111/ene.12770
- Lubbe, S. J., Escott-Price, V., Gibbs, J. R., Nalls, M. A., Bras, J., Price, T. R., et al. (2016). Additional rare variant analysis in Parkinson's disease cases with and without known pathogenic mutations: evidence for oligogenic inheritance. *Hum. Mol. Genet.* 25, 5483–5489.
- Luk, K. C., Kehm, V., Carroll, J., Zhang, B., O'Brien, P., Trojanowski, J. Q., et al. (2012). Pathological α -synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. *Science* 338, 949–953. doi: 10.1126/science.1227157
- MacLeod, D. A., Rhinn, H., Kuwahara, T., Zolin, A., Di Paolo, G., McCabe, B. D., et al. (2013). RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk. *Neuron* 77, 425–439. doi: 10.1016/j.neuron.2012.11.033
- Madero-Pérez, J., Fdez, E., Fernández, B., Ordóñez, A. J. L., Ramírez, M. B., Gómez-Suaga, P., et al. (2018a). Parkinson disease-associated mutations in LRRK2 cause centrosomal defects via Rab8a phosphorylation. *Mol. Neurodegen.* 13:3. doi: 10.1186/s13024-018-0235-y
- Madero-Pérez, J., Fernández, B., Lara Ordóñez, A. J., Fdez, E., Lobbastael, E., Baekelandt, V., et al. (2018b). RAB7L1-mediated relocalization of LRRK2 to the Golgi complex causes centrosomal deficits via RAB8A. *Front. Mol. Neurosci.* 11:417. doi: 10.3389/fnmol.2018.00417
- Magalhaes, J., Gegg, M. E., Migdalska-Richards, A., Doherty, M. K., Whitfield, P. D., and Schapira, A. H. (2016). Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease. *Hum. Mol. Genet.* 25, 3432–3445. doi: 10.1093/hmg/ddw185
- Manzoni, C., Denny, P., Lovering, R. C., and Lewis, P. A. (2015). Computational analysis of the LRRK2 interactome. *PeerJ* 3:e778. doi: 10.7717/peerj.778
- Manzoni, C., Mamais, A., Dihanich, S., Abeti, R., Soutar, M. P. M., Plun-Favreau, H., et al. (2013a). Inhibition of LRRK2 kinase activity stimulates macroautophagy. *Biochim. Biophys. Acta.* 1833, 2900–2910. doi: 10.1016/j.bbamcr.2013.07.020
- Manzoni, C., Mamais, A., Dihanich, S., McGoldrick, P., Devine, M. J., Zerle, J., et al. (2013b). Pathogenic Parkinson's disease mutations across the functional domains of LRRK2 alter the autophagic/lysosomal response to starvation. *Biochem. Biophys. Res. Commun.* 441, 862–866. doi: 10.1016/j.bbrc.2013.10.159

- Maroteaux, L., Campanelli, J. T., and Scheller, R. H. (1988). Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. *J. Neurosci.* 8, 2804–2815. doi: 10.1523/jneurosci.08-08-02804.1988
- Mata, I. F., Jang, Y., Kim, C. H., Hanna, D. S., Dorschner, M. O., Samii, A., et al. (2015). The RAB39B p.G192R mutation causes X-linked dominant Parkinson's disease. *Mol. Neurodegener.* 10:50. doi: 10.1186/s13024-015-0045-4
- Matej, R., Tesar, A., and Rusina, R. (2019). Alzheimer's disease and other neurodegenerative dementias in comorbidity: a clinical and neuropathological overview. *Clin. Biochem.* 73, 26–31. doi: 10.1016/j.clinbiochem.2019.08.005
- Mazzulli, J. R., Xu, Y.-H., Sun, Y., Knight, A. L., McLean, P. J., Caldwell, G. A., et al. (2011). Gaucher disease glucocerebrosidase and α -synuclein form a bidirectional pathogenic loop in synucleinopathies. *Cell* 146, 37–52. doi: 10.1016/j.cell.2011.06.001
- Mazzulli, J. R., Zunke, F., Tsunemi, T., Tokar, N. J., Jeon, S., Burbulla, L. F., et al. (2016). Activation of β -glucocerebrosidase reduces pathological α -synuclein and restores lysosomal function in Parkinson's patient midbrain neurons. *J. Neurosci.* 36, 7693–7706. doi: 10.1523/JNEUROSCI.0628-16.2016
- Miller, D. B., and O'Callaghan, J. P. (2015). Biomarkers of Parkinson's disease: present and future. *Metabolism* 64, S40–S46.
- Mir, R., Tonelli, F., Lis, P., Macartney, T., Polinski, N. K., Martinez, T. N., et al. (2018). The Parkinson's disease VPS35 [D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human. *Biochem. J.* 475, 1861–1883. doi: 10.1042/BCJ20180248
- Moehle, M. S., Webber, P. J., Tse, T., Sukar, N., Standaert, D. G., DeSilva, T. M., et al. (2012). LRRK2 inhibition attenuates microglial inflammatory responses. *J. Neurosci.* 32, 1602–1611. doi: 10.1523/jneurosci.5601-11.2012
- Murphy, K. E., Gysbers, A. M., Abbott, S. K., Tayebi, N., Kim, W. S., Sidransky, E., et al. (2014). Reduced glucocerebrosidase is associated with increased α -synuclein in sporadic Parkinson's disease. *Brain* 137, 834–848. doi: 10.1093/brain/awt367
- Nagle, M. W., Latourelle, J. C., Labadorf, A., Dumitriu, A., Hadzi, T. C., Beach, T. G., et al. (2016). The 4p16.3 Parkinson disease risk locus is associated with GAK expression and genes involved with the synaptic vesicle membrane. *PLoS One* 11:e0160925. doi: 10.1371/journal.pone.0160925
- Nakamura, S., Higashiyama, Y., Izumikawa, K., Seki, M., Kakeya, H., Yamamoto, Y., et al. (2008). The roles of the quorum-sensing system in the release of extracellular DNA, lipopolysaccharide, and membrane vesicles from *Pseudomonas aeruginosa*. *Jpn. J. Infect. Dis.* 61, 375–378.
- Nalls, M. A., Blauwendraat, C., Vallerga, C. L., Heilbron, K., Bandres-Ciga, S., Chang, D., et al. (2019). Expanding Parkinson's disease genetics: novel risk loci, genomic context, causal insights and heritable risk. *bioRxiv* [Preprint].
- Nalls, M. A., Pankratz, N., Lill, C. M., Do, C. B., Hernandez, D. G., Saad, M., et al. (2014). Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. *Nat. Genet.* 46, 989–993. doi: 10.1038/ng.3043
- Nguyen, M., and Krainc, D. (2018). LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinson's disease. *Proc. Natl. Acad. Sci. U.S.A.* 115, 5576–5581. doi: 10.1073/pnas.1717590115
- Noyce, A., and Bandopadhyay, R. (2017). "Parkinson's disease: basic pathomechanisms and a clinical overview," in *Neurodegenerative Diseases: Pathology, Mechanisms, and Potential Therapeutic Targets*, eds P. Beart, M. Robinson, M. Rattray, and N. J. Maragakis (Cham: Springer International Publishing), 55–92. doi: 10.1007/978-3-319-57193-5_3
- Ozelius, L. J., Senthil, G., Saunders-Pullman, R., Ohmann, E., Deligtisch, A., Tagliati, M., et al. (2006). LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. *N. Engl. J. Med.* 354, 424–425.
- Paisán-Ruiz, C., Jain, S., Evans, E. W., Gilks, W. P., Simón, J., Van Der Brug, M., et al. (2004). Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. *Neuron* 44, 595–600. doi: 10.1016/j.neuron.2004.10.023
- Pan, P. Y., Li, X., Wang, J., Powell, J., Wang, Q., Zhang, Y., et al. (2017). Parkinson's disease-associated LRRK2 hyperactive kinase mutant disrupts synaptic vesicle trafficking in ventral midbrain neurons. *J. Neurosci.* 37, 11366–11376. doi: 10.1523/JNEUROSCI.0964-17.2017
- Parkkinen, L., Pirttilä, T., Tervahauta, M., and Alafuzoff, I. (2005). Widespread and abundant alpha-synuclein pathology in a neurologically unimpaired subject. *Neuropathology* 25, 304–314. doi: 10.1111/j.1440-1789.2005.00644.x
- Pauli, D., Arrigo, A.-P., and Tissières, A. (1992). Heat shock response in *Drosophila*. *Experientia* 48, 623–629.
- Peng, C., Gathagan, R. J., and Lee, V. M.-Y. (2018). Distinct α -synuclein strains and implications for heterogeneity among α -synucleinopathies. *Neurobiol. Dis.* 109, 209–218. doi: 10.1016/j.nbd.2017.07.018
- Piano, A., Valbonesi, P., and Fabbri, E. (2004). Expression of cytoprotective proteins, heat shock protein 70 and metallothioneins, in tissues of *Ostrea edulis* exposed to heat and heavy metals. *Cell Stress Chaperones* 9:134. doi: 10.1379/483.1
- Politis, M., Wu, K., Molloy, S., Bain, G. P., Chaudhuri, K. R., and Piccini, P. (2010). Parkinson's disease symptoms: the patient's perspective. *Mov. Disord.* 25, 1646–1651. doi: 10.1002/mds.23135
- Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., et al. (1997). Mutation in the α -synuclein gene identified in families with Parkinson's disease. *Science* 276, 2045–2047. doi: 10.1126/science.276.5321.2045
- Popoff, V., Mardones, G. A., Bai, S. K., Chambon, V., Tenza, D., Burgos, P. V., et al. (2009). Analysis of articulation between clathrin and retromer in retrograde sorting on early endosomes. *Traffic* 10, 1868–1880. doi: 10.1111/j.1600-0854.2009.00993.x
- Quadri, M., Fang, M., Picillo, M., Olgiati, S., Breedveld, G. J., Graafland, J., et al. (2013). Mutation in the SYNJ1 gene associated with autosomal recessive, early-onset Parkinsonism. *Hum. Mutat.* 34, 1208–1215. doi: 10.1002/humu.22373
- Rajput, A., Ross, J. P., Bernales, C. Q., Rayaprolu, S., Soto-Ortolaza, A. I., Ross, O. A., et al. (2015). VPS35 and DNAJC13 disease-causing variants in essential tremor. *Eur. J. Hum. Genet.* 23, 887–888. doi: 10.1038/ejhg.2014.164
- Ramirez, A., Heimbach, A., Grundemann, J., Stiller, B., Hampshire, D., Cid, L. P., et al. (2006). Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. *Nat. Genet.* 38, 1184–1191. doi: 10.1038/ng1884
- Reed, X., Bandres-Ciga, S., Blauwendraat, C., and Cookson, M. R. (2019). The role of monogenic genes in idiopathic Parkinson's disease. *Neurobiol. Dis.* 124, 230–239. doi: 10.1016/j.nbd.2018.11.012
- Rey, N. L., Wesson, D. W., and Brundin, P. (2018). The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases. *Neurobiol. Dis.* 109, 226–248. doi: 10.1016/j.nbd.2016.12.013
- Rideout, H. J., and Stefanis, L. (2014). The neurobiology of LRRK2 and its role in the pathogenesis of Parkinson's disease. *Neurochem. Res.* 39, 576–592. doi: 10.1007/s11064-013-1073-5
- Rodman, J. S., and Wandinger-Ness, A. (2000). Rab GTPases coordinate endocytosis. *J. Cell Sci.* 113, 183–192.
- Roosen, D. A., Blauwendraat, C., Cookson, M. R., and Lewis, P. A. (2019). DNAJC proteins and pathways to parkinsonism. *FEBS J.* 286, 3080–3094. doi: 10.1111/febs.14936
- Ross, J. P., Dupre, N., Dauvilliers, Y., Strong, S., Ambalavanan, A., Spiegelman, D., et al. (2016). Analysis of DNAJC13 mutations in French-Canadian/French cohort of Parkinson's disease. *Neurobiol. Aging* 45, 212.e13–212.e17. doi: 10.1016/j.neurobiolaging.2016.04.023
- Sardi, S. P., Clarke, J., Kinnecom, C., Tamsett, T. J., Li, L., Stanek, L. M., et al. (2011). CNS expression of glucocerebrosidase corrects α -synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. *Proc. Natl. Acad. Sci. U.S.A.* 108, 12101–12106. doi: 10.1073/pnas.1108197108
- Schapira, A. H., Chaudhuri, K. R., and Jenner, P. (2017). Non-motor features of Parkinson disease. *Nat. Rev. Neurosci.* 18:435. doi: 10.1038/nrn.2017.62
- Schimmöller, F., Simon, I., and Pfeffer, S. R. (1998). Rab GTPases, directors of vesicle docking. *J. Biol. Chem.* 273, 22161–22164. doi: 10.1074/jbc.273.35.22161
- Schneider, S. A., and Alcalay, R. N. (2017). Neuropathology of genetic synucleinopathies with parkinsonism: review of the literature. *Mov. Disord.* 32, 1504–1523. doi: 10.1002/mds.27193
- Seabra, M. C., Mules, E. H., and Hume, A. N. (2002). Rab GTPases, intracellular traffic and disease. *Trends Mol. Med.* 8, 23–30. doi: 10.1016/s1471-4914(01)02227-4
- Seaman, M. N., McCaffery, J. M., and Emr, S. D. (1998). A membrane coat complex essential for endosome-to-Golgi retrograde transport in yeast. *J. Cell Biol.* 142, 665–681. doi: 10.1083/jcb.142.3.665

- Shahmoradian, S. H., Lewis, A. J., Genoud, C., Graff-Meyer, A., Hench, J., Moors, T., et al. (2018). Lewy pathology in Parkinson's disease consists of a crowded organellar, membranous medley. *Biorxiv/Preprints*
- Shahmoradian, S. H., Lewis, A. J., Genoud, C., Hench, J., Moors, T. E., Navarro, P. P., et al. (2019). Lewy pathology in Parkinson's disease consists of crowded organelles and lipid membranes. *Nat. Neurosci.* 22, 1099–1109. doi: 10.1038/s41593-019-0423-2
- Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., et al. (2009). Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. *N. Engl. J. Med.* 361, 1651–1661.
- Simon-Sanchez, J., Schulte, C., Bras, J. M., Sharma, M., Gibbs, J. R., Berg, D., et al. (2009). Genome-wide association study reveals genetic risk underlying Parkinson's disease. *Nat. Genet.* 41, 1308–1312. doi: 10.1038/ng.487
- Singleton, A., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., et al. (2003). α -Synuclein locus triplication causes Parkinson's disease. *Science* 302, 841–841. doi: 10.1126/science.1090278
- Soldner, F., Stelzer, Y., Shivalila, C. S., Abraham, B. J., Latourelle, J. C., Barrasa, M. I., et al. (2016). Parkinson-associated risk variant in distal enhancer of α -synuclein modulates target gene expression. *Nature* 533, 95–99. doi: 10.1038/nature17939
- Soukup, S.-F., and Verstreken, P. (2017). EndoA/Endophilin-A creates docking stations for autophagic proteins at synapses. *Autophagy* 13, 971–972. doi: 10.1080/15548627.2017.1286440
- Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., and Goedert, M. (1998). α -Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. *Proc. Natl. Acad. Sci. U.S.A.* 95, 6469–6473. doi: 10.1073/pnas.95.11.6469
- Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., and Goedert, M. (1997). α -Synuclein in Lewy bodies. *Nature* 388, 839–840.
- Steger, M., Tonelli, F., Ito, G., Davies, P., Trost, M., Vetter, M., et al. (2016). Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases. *eLife* 5:e12813. doi: 10.7554/eLife.12813
- Südhof, T. C. (2012). Calcium control of neurotransmitter release. *Cold Spring Harb. Perspect. Biol.* 4:a011353. doi: 10.1101/cshperspect.a011353
- Sun, J., Wang, L., Bao, H., Premi, S., Das, U., Chapman, E. R., et al. (2019). Functional cooperation of alpha-synuclein and VAMP2 in synaptic vesicle recycling. *Proc. Natl. Acad. Sci. U.S.A.* 116, 11113–11115. doi: 10.1073/pnas.1903049116
- Surmeier, D. J., and Sulzer, D. (2013). The pathology roadmap in Parkinson disease. *Prion* 7, 85–91. doi: 10.4161/pri.23582
- Tao-Cheng, J. H. (2006). Activity-related redistribution of presynaptic proteins at the active zone. *Neuroscience* 141, 1217–1224. doi: 10.1016/j.neuroscience.2006.04.061
- Theillet, F.-X., Binolfi, A., Bekei, B., Martorana, A., Rose, H. M., Stuijver, M., et al. (2016). Structural disorder of monomeric α -synuclein persists in mammalian cells. *Nature* 530, 45–50. doi: 10.1038/nature16531
- Tofaris, G. K. (2012). Lysosome-dependent pathways as a unifying theme in Parkinson's disease. *Mov. Disord.* 27, 1364–1369. doi: 10.1002/mds.25136
- Tsika, E., Kannan, M., Foo, C. S.-Y., Dikeman, D., Glauser, L., Gellhaar, S., et al. (2014). Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration. *Neurobiol. Dis.* 71, 345–358. doi: 10.1016/j.nbd.2014.08.027
- Tsuji, S., Choudary, P. V., Martin, B. M., Stubblefield, B. K., Mayor, J. A., Barranger, J. A., et al. (1987). A mutation in the human glucocerebrosidase gene in neuronopathic Gaucher's disease. *N. Engl. J. Med.* 316, 570–575. doi: 10.1056/NEJM198703053161002
- Usenovic, M., Tresse, E., Mazzulli, J. R., Taylor, J. P., and Krainc, D. (2012). Deficiency of ATP13A2 leads to lysosomal dysfunction, alpha-synuclein accumulation, and neurotoxicity. *J. Neurosci.* 32, 4240–4246. doi: 10.1523/JNEUROSCI.5575-11.2012
- Vagnozzi, A. N., Li, J.-G., Chiu, J., Razmpour, R., Warfield, R., Ramirez, S. H., et al. (2019). VPS35 regulates tau phosphorylation and neuropathology in tauopathy. *Mol. Psychiatry* 24, 877–884. doi: 10.1038/s41380-019-0453-x
- Vargas, K. J., Schrod, N., Davis, T., Fernandez-Busnadiego, R., Taguchi, Y. V., Laugs, U., et al. (2017). Synucleins have multiple effects on presynaptic architecture. *Cell Rep.* 18, 161–173. doi: 10.1016/j.celrep.2016.12.023
- Vilariño-Güell, C., Rajput, A., Milnerwood, A. J., Shah, B., Szu-Tu, C., Trinh, J., et al. (2013). DNAJC13 mutations in Parkinson disease. *Hum. Mol. Genet.* 23, 1794–1801. doi: 10.1093/hmg/ddt570
- Vilariño-Güell, C., Wider, C., Ross, O. A., Dachselt, J. C., Kachergus, J. M., Lincoln, S. J., et al. (2011). VPS35 mutations in Parkinson disease. *Am. J. Hum. Genet.* 89, 162–167.
- Wallings, R., Manzoni, C., and Bandopadhyay, R. (2015). Cellular processes associated with LRRK2 function and dysfunction. *FEBS J.* 282, 2806–2826. doi: 10.1111/febs.13305
- Wang, C., Kang, X., Zhou, L., Chai, Z., Wu, Q., Huang, R., et al. (2018). Synaptotagmin-11 is a critical mediator of parkin-linked neurotoxicity and Parkinson's disease-like pathology. *Nat. Commun.* 9:81.
- Wilson, G. R., Sim, J. C., McLean, C., Giannandrea, M., Galea, C. A., Riseley, J. R., et al. (2014). Mutations in RAB39B cause X-linked intellectual disability and early-onset Parkinson disease with α -synuclein pathology. *Am. J. Hum. Genet.* 95, 729–735. doi: 10.1016/j.ajhg.2014.10.015
- Yabuno, Y., Uchihashi, T., Sasakura, T., Shimizu, H., Naito, Y., Fukushima, K., et al. (2019). Clathrin heavy chain phosphorylated at T606 plays a role in proper cell division. *Cell Cycle* 18, 1976–1994. doi: 10.1080/15384101.2019.1637201
- Zarranz, J. J., Alegre, J., Gómez-Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., et al. (2014). The new mutation, E46K, of α -synuclein causes Parkinson and Lewy body dementia. *Ann. Neurol.* 55, 164–173. doi: 10.1002/ana.10795
- Zhou, C., Huang, Y., and Przedborski, S. (2008). Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. *Ann. N. Y. Acad. Sci.* 1147, 93. doi: 10.1196/annals.1427.023
- Zimprich, A., Benet-Pagès, A., Struhal, W., Graf, E., Eck, S. H., Offman, M. N., et al. (2011). A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. *Am. J. Hum. Genet.* 89, 168–175. doi: 10.1016/j.ajhg.2011.06.008
- Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., et al. (2004). Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. *Neuron* 44, 601–607. doi: 10.1016/j.neuron.2004.11.005

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Ebanks, Lewis and Bandopadhyay. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.